Serina Therapeutics Q3 net loss attributable to common stockholders widens 68% to $7.9 million
Serina Therapeutics Q3 net loss attributable to common stockholders widens 68% to $7.9 million S
Serina Therapeutics Q3 net loss attributable to common stockholders widens 68% to $7.9 million S